Impact of Medicaid Unwinding on Medication Treatment for Opioid Use Disorder
A recent study links Medicaid unwinding to reduced initiation and continuation of medication treatment for opioid use disorder, emphasizing the importance of sustained access amidst policy changes.
Recent research by the RAND Corporation highlights significant shifts in medication treatment for opioid use disorder (OUD) following the end of pandemic-era Medicaid enrollment protections. The study reveals that as states resumed standard Medicaid procedures, over 25 million Americans experienced disenrollment, which correlates with notable declines in both initiation and continuation of treatment with medications like buprenorphine.
The investigation, which analyzed prescription data from all 50 states and the District of Columbia spanning from January 2021 to December 2023, found that the overall number of treatment episodes paid for by Medicaid decreased after unwinding began. States with the highest levels of disenrollment saw the largest reductions. Specifically, there was a 2.6% decrease in new Medicaid-paid treatment episodes during the six months following unwinding, with an even more significant 3.9% drop in states most affected by disenrollment.
While some individuals disenrolled from Medicaid may have accessed other payment methods for their medication, the data suggest that shifts in treatment episodes are not fully offset by alternative sources such as out-of-pocket payments or private insurance. The findings underscore a concerning trend: the ending of Medicaid continuous coverage is associated with decreased treatment engagement for individuals battling opioid addiction.
The study emphasizes the critical need to ensure sustained access to life-saving medications, especially as federal legislation predicts that up to 10 million Americans could lose Medicaid coverage by 2034. Medication-assisted treatment, particularly buprenorphine, remains the most effective approach for managing opioid use disorder, with Medicaid covering approximately 40% of these treatments.
Lead researcher Rachel K. Landis notes that the decline in treatment episodes correlates strongly with Medicaid disenrollment, especially in states experiencing the greatest unwinding. Experts warn that such disruptions could hinder progress in combating the opioid overdose crisis and highlight the importance of policy measures that maintain access to essential treatments.
[Source: https://medicalxpress.com/news/2025-09-medicaid-unwinding-medication-treatment-opioid.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
AI-Assisted Chest X-ray Enhances Diagnosing Achalasia
A new AI-powered approach utilizing plain chest X-rays offers a non-invasive, accurate method for early diagnosis of achalasia, potentially transforming screening and treatment outcomes.
Low Prescription Rates of Obesity Medications in Adolescents Highlight Treatment Gaps
Despite increasing awareness, prescription rates for obesity medications in adolescents remain extremely low, with only 0.5% receiving such treatment in 2023. Recent research highlights treatment disparities and a potential gap in effective obesity management among youth.
Zilebesiran Shows Potential in Lowering Blood Pressure in High-Risk Hypertensive Patients
Clinical trial data suggests that zilebesiran, an investigational RNA therapy, may help lower blood pressure in high-risk hypertensive patients, paving the way for new treatment options.
Impact of Adolescent Antidepressant Use on Adult Pain Sensitivity
A new study reveals that antidepressant use during adolescence, especially Prozac, may increase pain sensitivity in adulthood, highlighting the need for further research into long-term effects of psychiatric medications.